Table 2.
The relationship between testosterone/estradiol levels and MMSE score in subgroups stratified by VRFs
| Subgroups | Q1 a | Q2 a | Q3 a | Q4 a | P- trend |
|---|---|---|---|---|---|
| (The lowest) | β (95% CI) | β (95% CI) | β (95% CI) | ||
| Participants without VRF (N = 77) b | |||||
| Testosterone | |||||
| Model 1 | Ref. | -1.28 (-5.10, 2.54) | 0.98 (-2.34, 4.30) | 0.18 (-3.03, 3.39) | 0.65 |
| Model 2 | Ref. | -1.32 (-5.25, 2.61) | 0.72 (-3.01, 4.45) | -0.19 (-0.91, 3.52) | 0.83 |
| Estradiol | |||||
| Model 1 | Ref. | 1.91 (-1.39, 5.20) | 0.95 (-2.44, 4.33) | 1.26 (-1.83, 4.34) | 0.56 |
| Model 2 | Ref. | 1.65 (-1.84, 5.14) | 0.49 (-3.43, 4.40) | 1.06 (-2.47, 4.59) | 0.68 |
| Participants with one VRF (N = 103) c | |||||
| Testosterone | |||||
| Model 1 | Ref. | 1.96 (-0.07, 4.00) | 3.02 (0.83, 5.21)** | 2.34 (-0.07, 4.75) | 0.027 |
| Model 2 | Ref. | 1.57 (-0.50, 3.65) | 2.74 (0.44, 5.03)* | 2.21 (-0.52, 4.95) | 0.07 |
| Estradiol | |||||
| Model 1 | Ref. | 1.09 (-1.29, 3.48) | 2.52 (0.40, 4.65)* | 1.15 (-1.09, 3.38) | 0.17 |
| Model 2 | Ref. | 0.34 (-2.16, 2.84) | 1.75 (-0.46, 3.96) | 0.16 (-2.39, 2.72) | 0.66 |
| Participants with two or more VRFs (N = 44) c | |||||
| Testosterone | |||||
| Model 1 | Ref. | 1.44 (-1.42, 4.30) | 0.99 (-3.17, 5.15) | 3.29 (-0.04, 6.62) | 0.07 |
| Model 2 | Ref. | 1.82 (-0.93, 4.58) | 0.82 (-3.18, 4.81) | 3.01 (-0.33, 6.34) | 0.19 |
| Estradiol | |||||
| Model 1 | Ref. | 2.71 (-0.23, 5.65) | 4.17 (1.20, 7.14)* | 2.46 (-1.20, 6.12) | 0.052 |
| Model 2 | Ref. | 3.03 (0.08, 5.99) | 3.82 (0.82, 6.81)* | 1.58 (-2.22, 5.38) | 0.15 |
a. Quartile boundaries for testosterone Q1/2 4.1 ng/ml, Q2/3 5.6 ng/ml, and Q3/4 6.8ng/ml; quartile boundaries for estradiol Q1/2 25.7 pg/ml, Q2/3 32.7 pg/ml, and Q3/4 38.9 pg/ml
b. In the subgroup without VRF, Model 1 adjusted for age, education, BMI, WC, and depression; Model 2 additionally adjusted for testosterone (for estradiol) or estradiol (for testosterone)
c. In the subgroup with one VRF and two or more VRFs, Model 1 adjusted for age, education, BMI, WC, depression, diabetes mellitus, hypertension, coronary heart disease, and stroke; Model 2 adjusted for testosterone (for estradiol) or estradiol (for testosterone)
*P <.05, ** P <.01